Levera Injection contains Levetiracetam 100 mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. This injectable formulation is intended for intravenous administration when oral administration is not feasible, ensuring rapid onset of action. Levera Injection is typically used as adjunctive therapy in adults and pediatric patients aged one month and older. The dosage should be individualized based on clinical response and renal function, with careful monitoring to minimize adverse effects. Common side effects may include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation. Hypersensitivity reactions, although rare, require immediate discontinuation of the drug. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levera Injection should be administered under medical supervision with appropriate seizure monitoring. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any of the excipients. This formulation provides an effective and well-tolerated option for seizure control in clinical settings requiring parenteral therapy.